EGFR and lung adenocarcinoma: After being compared with the results of the EGFR-mutant lung adenocarcinoma patients treated by gefitinib alone, dual drugs of gefitinib and dasatinib achieved the better response rate and duration as compared with gefitinib alone (Figures 7Q, R), which led to a better prognosis for OS (Figure 7S).